Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma
-
- Sachiyo Yoshio
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Tomonari Shimagaki
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Ryuki Hashida
- Division of Rehabilitation Department of Rehabilitation Kurume University School of Medicine Kurume Japan
-
- Takumi Kawaguchi
- Division of Gastroenterology Department of Medicine Kurume University School of Medicine Kurume Japan
-
- Yuriko Tsutsui
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Yuzuru Sakamoto
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Yuichi Yoshida
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Hironari Kawai
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Shiori Yoshikawa
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Taiji Yamazoe
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Taizo Mori
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Yosuke Osawa
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
-
- Shinji Itoh
- Department of Surgery and Science Graduate School of Medical Sciences, Kyushu University Fukuoka Japan
-
- Moto Fukai
- Department of Gastroenterological Surgery I Hokkaido University Graduate School of Medicine Sapporo Japan
-
- Tomoharu Yoshizumi
- Department of Surgery and Science Graduate School of Medical Sciences, Kyushu University Fukuoka Japan
-
- Akinobu Taketomi
- Department of Gastroenterological Surgery I Hokkaido University Graduate School of Medicine Sapporo Japan
-
- Masaki Mori
- Department of Surgery and Science Graduate School of Medical Sciences, Kyushu University Fukuoka Japan
-
- Tatsuya Kanto
- Department of Liver Disease The Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Ichikawa Japan
この論文をさがす
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>In patients with liver cirrhosis, high levels of serum myostatin are associated with poor prognosis. We aimed to clarify the influence of myostatin on the prognosis of patients with non‐alcoholic fatty liver disease–hepatocellular carcinoma (NAFLD‐HCC) without cirrhosis and on the progression of liver fibrosis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Serum myostatin levels were evaluated in 234 patients who underwent primary surgical resection for single HCC. To clarify the impact of myostatin on liver fibrosis, we established human primary liver fibroblasts from resected livers, and cultured them in the presence of myostatin.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The median age was 67.4 years, the median L3 skeletal muscle mass index was 44.4 cm<jats:sup>2</jats:sup>/m<jats:sup>2</jats:sup>, and the median body mass index was 23.4 kg/m<jats:sup>2</jats:sup>. Eighty‐two (35.0%) patients had sarcopenia (L3 skeletal muscle mass index: men <42, women <38 cm<jats:sup>2</jats:sup>/m<jats:sup>2</jats:sup>). The etiologies of liver disease were hepatitis B virus (<jats:italic>n</jats:italic> = 61), hepatitis C virus (<jats:italic>n</jats:italic> = 86), and non‐B non‐C hepatitis (<jats:italic>n</jats:italic> = 87) including NAFLD (<jats:italic>n</jats:italic> = 74). High preoperative serum myostatin and vascular invasion were independent predictors of poor overall survival (OS). High serum myostatin was associated with poor OS in patients with no sarcopenia (<jats:italic>n</jats:italic> = 152). In patients without advanced liver fibrosis (Fibrosis stage, 0–2; <jats:italic>n</jats:italic> = 58), high levels of serum myostatin were also associated with poor OS, regardless of sarcopenia. Serum myostatin levels were increased with the progression of liver fibrosis. Liver fibroblasts were activated and produced collagen following stimulation with myostatin.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In patients with NAFLD‐HCC without advanced liver fibrosis, high levels of serum myostatin were associated with poor OS. Myostatin activated primary fibroblasts and stimulated collagen production.</jats:p></jats:sec>
収録刊行物
-
- Hepatology Research
-
Hepatology Research 51 (7), 803-812, 2021-05-25
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360576118814699392
-
- ISSN
- 1872034X
- 13866346
-
- データソース種別
-
- Crossref
- KAKEN